
ACIM advises the Secretary of Health and Human Services on department activities and programs directed at reducing infant mortality and improving the health status of pregnant women and infants. ACIM represents a public-private partnership at the highest level to provide guidance and focus attention on the policies and resources required to address the reduction of infant mortality and the improvement of the health status of pregnant women and infants. With a focus on life course, the ACIM addresses disparities in maternal health to improve maternal health outcomes, including preventing and reducing maternal mortality and severe maternal morbidity. ACIM provides advice on how best to coordinate myriad federal, state, local, and private programs and efforts that are designed to deal with the health and social problems impacting infant mortality and maternal health, including implementation of the Healthy Start program and maternal and infant health objectives from the National Health Promotion and Disease Prevention Objectives (i.e., Healthy People 2030).

The agenda for the September 21–22, 2021, meeting is being finalized and may include the following topics: Federal program updates; discussion of recommendations by ACIM to the Secretary; fatality review programs; health of indigenous mothers and infants; financing of care; and patient-physician racial concordance in health care. Refer to the ACIM website for any updated information concerning the meeting.

Members of the public will have the opportunity to provide written or oral comments. Requests to submit a written statement or make oral comments to the ACIM should be sent to Vanessa Lee, using the email address above at least three business days prior to the meeting. Public participants may submit written statements in advance of the scheduled meeting by emailing SACIM@hrsa.gov. Oral comments will be honored in the order they are requested and may be limited as time allows.

Individuals who plan to attend and need special assistance or another reasonable accommodation should notify Vanessa Lee at the contact information listed above at least 10 business days prior to the meeting.

Maria G. Button,
Director, Executive Secretariat.

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Dental & Craniofacial Research; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Advisory Dental and Craniofacial Research Council, September 9, 2021, 10:00 a.m. to September 9, 2021, 4:00 p.m., National Institutes of Health, National Institute of Dental and Craniofacial Res., 6701 Democracy Blvd., Bethesda, MD 20892 which was published in the Federal Register on August 13, 2021, FR Doc. 2021–17302, 86 FR 44736.

This meeting is being amended to change the times of the Open and Closed sessions. The Open session will be from 9:00 a.m. to 2:30 p.m. and will be videocast and can be accessed from the NIH Videocasting and Podcasting website (http://videocast.nih.gov/). The Closed session will be from 2:45 p.m. to 3:30 p.m. The meeting is partially Closed to the public.

Melanie J. Pantoya,
Program Analyst, Office of Federal Advisory Committee Policy.

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day Comment Request Electronic Individual Development Plan (eIDP) (National Eye Institute)

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: In compliance with the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below.

DATES: Comments regarding this information collection are best assured of having their full effect if received within 30-days of the date of this publication.

ADDRESSES: Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/do/PRAMain. Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function.

FOR FURTHER INFORMATION CONTACT: To obtain a copy of the data collection plans and instruments, submit comments in writing, or request more information on the proposed project, contact: Dr. Cesar E. Perez-Gonzalez, Training Director, Office of the Scientific Director, National Eye Institute, NIH, Building 31, Room 6A22, MSC 0250, Bethesda, Maryland 20892 or call non-toll-free number (301) 491–6763 or Email your request, including your address to: cesarp@nei.nih.gov. Formal requests for additional plans and instruments must be requested in writing.

SUPPLEMENTARY INFORMATION: This proposed information collection was previously published in the Federal Register on May 24, 2021, page 27856–27857 (86 FR 27856) and allowed 60 days for public comment. No public comments were received. The purpose of this notice is to allow an additional 30 days for public comment.

The National Eye Institute (NEI), National Institutes of Health, may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number.

In compliance with Section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below.


Need and Use of Information Collection: The National Eye Institute’s (NEI) Office of the Scientific Director (OSD) goal is to train the next generation of vision researchers and ophthalmologists. Trainees who participate in NEI research come with different levels of education (student, postbaccalaureate, predoctoral including graduate and medical students, postdoctoral fellows) and for different amounts of time (6 months to 5 years). Training at the NEI focuses on scientific and professional skill development. To enhance their chances of obtaining their ideal career, completing an annual Individual
Development Plan (IDP) is an important step in helping a trainee’s career and professional development and is standard practice in graduate and postdoctoral education. An IDP is an effective tool for trainees to think about their career goals and skills needed to achieve them during their time at the NEI. Trainees work together with their research mentor to organize and summarize their research projects, consider career goals, and set training goals and expectations, both for the mentee and mentor.

This information collection request is to implement an electronic Individual Development Plan (eIDP). The data collected comes from a detailed questionnaire focused on responses to professional goals and expectations while they are at the NEI. It is expected that the trainees will complete the eIDP annually and by doing so, it will help enhance the effectiveness of their training by setting clear goals that can be monitored not only by the trainee themselves but also by their mentor, the Training Director, and their Administrative Officer. In addition to this eIDP, the system will also implement an electronic exit survey. The data collected comes from a detailed questionnaire focused on responses to questions focused on trainee mentoring and professional experiences at the NEI as well as their plans after they depart. It is expected that the trainees will complete at the end of their tenure and that by doing so, the NEI Training Program can learn about ways to improve career development opportunities for future trainees as well as learn more about trainee job choices to better advise fellows. Additionally, we can use the survey to help determine mentor effectiveness and help identify problems in mentoring at the NEI.

OMB approval is requested for 3 years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 213.

### ESTIMATED ANNUALIZED BURDEN HOURS

<table>
<thead>
<tr>
<th>Type of respondent</th>
<th>Number of respondents</th>
<th>Number of responses per respondent</th>
<th>Average time per response (in hours)</th>
<th>Total annual burden hour</th>
</tr>
</thead>
<tbody>
<tr>
<td>eIDP (Attachment 1)</td>
<td>Individuals</td>
<td>150</td>
<td>1</td>
<td>150</td>
</tr>
<tr>
<td>Exit Survey Part 1 (Attachment 2)</td>
<td>Individuals</td>
<td>150</td>
<td>1</td>
<td>5/60</td>
</tr>
<tr>
<td>Exit Survey Part 2 (Attachment 3)</td>
<td>Individuals</td>
<td>150</td>
<td>1</td>
<td>20/60</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>150</td>
<td>150</td>
<td></td>
</tr>
</tbody>
</table>


**Cesar E. Perez-Gonzalez,**

Training Director, National Eye Institute, National Institutes of Health.

[FR Doc. 2021-16393 Filed 8-25-21; 8:45 am]

BILLING CODE 4140–01–P

---

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Cancer Institute; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Cancer Institute Special Emphasis Panel; SEP–6: NCI Clinical and Translational Cancer Research.

**Date:** October 12, 2021.

**Time:** 11:00 a.m. to 4:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W242, Rockville, Maryland 20850 (Telephone Conference Call).

**Contact Person:** Jeffrey E. DeClue, Ph.D., Scientific Review Officer, Research Technology and Contract Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W114, Rockville, Maryland 20850. decluej@mail.nih.gov.

**Name of Committee:** National Cancer Institute Special Emphasis Panel; SEP–1: NCI Clinical and Translational Cancer Research.

**Date:** October 28, 2021.

**Time:** 10:00 a.m. to 4:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W242, Rockville, Maryland 20850 (Telephone Conference Call).

**Contact Person:** Zhiqiang Zou, M.D., Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W242, Rockville, Maryland 20850. 240–276–6372, zouzhq@mail.nih.gov.

**Name of Committee:** National Cancer Institute Special Emphasis Panel; SEP–2: NCI Clinical and Translational Cancer Research.

**Date:** November 3, 2021.

**Time:** 9:30 a.m. to 7:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W114, Rockville, Maryland 20850 (Telephone Conference Call).

**Contact Person:** Byeeong-Chel Lee, Ph.D., Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W238, Rockville, Maryland 20850, 240–276–7755. byeeong-chel.lee@nih.gov.

**Name of Committee:** National Cancer Institute Special Emphasis Panel; Proteogenomic: Tumor Analysis.

**Date:** November 3, 2021.

**Time:** 9:30 a.m. to 7:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W114, Rockville, Maryland 20850 (Telephone Conference Call).

**Contact Person:** Zhiqiang Zou, M.D., Ph.D., Scientific Review Officer, Research Technology and Contract Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W114, Rockville, Maryland 20850. 240–276–6372, decluej@mail.nih.gov.

**Name of Committee:** National Cancer Institute Special Emphasis Panel; R03 Omnibus and R21 Clinical and Translational Research.

**Date:** November 3, 2021.

**Time:** 10:00 a.m. to 4:30 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W556, Rockville, Maryland 20850 (Telephone Conference Call).

**Contact Person:** Cesar E. Perez-Gonzalez, Training Director, National Eye Institute, National Institutes of Health.

**Name of Committee:** National Cancer Institute Special Emphasis Panel; Metastasis Research Network (U54).

**Date:** October 28–29, 2021.

**Time:** 10:00 a.m. to 6:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W238, Rockville, Maryland 20850 (Telephone Conference Call).

**Contact Person:** Kamal Datta, M.D., Scientific Review Officer, Program